Transboundary and Emerging Diseases | Boehringer Ingelheim US
Click here to find out more on how Boehringer Ingelheim fights transboundary and emerging diseases through cutting-edge technologies.
Search
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
We nurture innovative ideas
At Boehringer Ingelheim, we know to really make a difference we need to innovate. That’s why we embrace and invest in innovation every single day.
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
Shanghai
Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
Our Responsibility
Our Responsibility
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics For Geographic Atrophy, a Leading Cause of Blindness Worldwide
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics For Geographic Atrophy, a Leading Cause of Blindness Worldwide
Boehringer’s unique approach to innovation
Boehringer’s unique approach to driving patient-centric innovation
Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US
Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.
Retinal Diseases
Retinal Diseases
Swine
Swine
FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US
FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.
Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
Medicines reach record number of people, net sales rise
Boehringer Ingelheim Launches External Innovation Hub in China
Boehringer Ingelheim Launches External Innovation Hub in China
How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health
Interview with Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health on the role of partnerships in driving innovation.
Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
Patient Centricity
Patient Centricity
About Us
Click here to discover more about Boehringer Ingelheim and our headquarters and largest U.S subsidiary in Connecticut.
New consortium EUbOPEN will provide tools to unlock disease biolog
New consortium EUbOPEN will provide tools to unlock disease biolog
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Dr. Hsing-Jung Chen-Engerer
Dr. Hsing-Jung Chen-Engerer of Research & Development speaks about his fulfilling career with Boehringer Ingelheim.
Dirk Stenkamp
Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.